Navigation Links
KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results
Date:8/11/2008

M) will make a significant contribution to Ther-Rx revenues during the second half of fiscal 2009.

ETHEX Corporation -- 53% Net Sales Growth Due to Metoprolol Succinate

ETHEX Corporation net sales of $92.3 million in the first quarter represented a 52.6% increase compared to the prior year first quarter of $60.5 million. Sales growth during the quarter was impacted by volume growth from the sale of all four strengths of metoprolol succinate extended-release tablets, which contributed $35.5 million in net revenues during the quarter, offset in part by the reduced level of sales from our discontinued cough/cold product line.

ETHEX's cough/cold product line, except for one product, was discontinued earlier this calendar year following a shift in FDA policy on products containing guaifenesin. Our currently marketed generic cough/cold product generated net revenues of $0.5 million during the quarter, compared with sales of the entire cough/cold product line of $9.3 million for the first quarter of fiscal 2008.

ETHEX's profitability remained strong for another quarter as measured by its gross profit margins of 60.5%, compared to gross margins of 56.0% in the first quarter of fiscal 2008.

The ETHEX pipeline remains strong. Last year we filed 16 ANDA's and this year we expect to file another 16 ANDA's. During this fiscal year, we expect six ANDA approvals, following five ANDA approvals received by KV in our preceding fiscal year. In addition, ETHEX believes it is the first to file for a number of Paragraph IV generic products with significant revenue contribution potential.

Outlook for the Year

The Company currently expects to report net revenue of between $650 million and $675 million and net income per diluted Class A share of between $1.65 and $1.75 for the fiscal year ending March 31, 2009. Although KV historically has not issued revenue or earnings guidance, in light of potential competitive challenges related to certain
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... 29, 2015 , ... Healthpointe, one of Southern California’s leading ... MD., PhD into their world-class multidisciplinary team of physicians and specialists. Dr. ... Irwindale and La Tijera-Los Angeles. , Orthopedic surgeons of Healthpointe, such as ...
(Date:6/29/2015)... ... 2015 , ... Mediaplanet has released the first edition of ... 12-page, glossy, full-color special section hit newsstands Friday, June 26th, and was distributed ... copies, with an estimated readership of 1.3 million. The digital component is being ...
(Date:6/29/2015)... NEW YORK, NEW YORK (PRWEB) , ... June ... ... obstructive sleep apnea (OSA) is now being offered at NewYork-Presbyterian/Weill Cornell Medical Center. ... and Drug Administration and is an alternative to continuous positive airway pressure (CPAP), ...
(Date:6/29/2015)... ... 2015 , ... National HealthCare Associates recently released a list ... 40-center nursing home group. Sixteen of their centers were rated “Best in Class” ... one or more customer service areas. Those centers received the prestigious “Customer Experience ...
(Date:6/29/2015)... ... 2015 , ... With Urgent Care Medicine now serving a vital role in ... Urgent Care Medicine and the Medical Society of Delaware to provide its latest professional ... health care professionals. , According to Matthew Bader, Exam Master CEO and President, “This ...
Breaking Medicine News(10 mins):Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Mediaplanet partners with USA TODAY and Kris Letang to raise awareness about the risk of heart attack and stroke 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 3
... , HARBIN, China, Sept. 9 ... CKGT), a vertically integrated grower,developer, manufacturer and marketer of ... the Rodman and Renshaw Annual Global Investment,Conference to be ... Kangtai,Cactus Biotech will present as part of the Asia ...
... , , Obesity Experts ... , SILVER SPRING, Md., Sept. 9 ... to Overcome and Prevent (STOP) Obesity Alliance, and two former US Surgeons ... act on the inclusion of obesity as the largest and most urgent ...
... , CAMBRIDGE, Mass., Sept. 9 ... enterprise content compliance software solutions for ... Software-as-a-Service (SaaS) solution for managing clinical trial disclosure requirements. The ... a robust offering that automates compliance with global regulatory mandates ...
... , , TARRYTOWN, N.Y., Sept. 9 Bayer ... (R) 2 blood glucose meters -- Pink and Purple. , ... same unique easy to use(1) features as the original silver BREEZE2 ... the meter itself, so users do not have to handle individual ...
... They can get variety of illnesses from the sexually transmitted ... A U.S. health advisory committee on Wednesday will discuss whether ... transmitted human papillomavirus (HPV), for use in boys as well ... has asked the U.S. Food and Drug Administration to approve ...
... , , TITUSVILLE, ... to impact up to 20 percent of children(1) and 4 percent ... underdiagnosed: researchers estimate up to 20 percent of U.S. school-aged children ... but only 7.8 percent report receiving an ADHD diagnosis.(3) Meanwhile, it ...
Cached Medicine News:Health News:China Kangtai Cactus Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference in New York on September 11, 2009 2Health News:China Kangtai Cactus Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference in New York on September 11, 2009 3Health News:Obesity Driving America's Healthcare to a Tipping Point 2Health News:Obesity Driving America's Healthcare to a Tipping Point 3Health News:Obesity Driving America's Healthcare to a Tipping Point 4Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 2Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 3Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 4Health News:Bayer's BREEZE(R)2 Meter Available in Two New Vibrant Colors for a Limited Time 2Health News:FDA Panel Weighs Approving HPV Vaccine for Males 2Health News:FDA Panel Weighs Approving HPV Vaccine for Males 3Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 2Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 3Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 4Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 5
(Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Medicine Products: